Maria Vila's Contact Details

Maria Vila's Company Details

Myogem Health Company S.L.

Mollet del Vallès, Catalunya, Spain • 4 Employees
Pharmaceuticals

Myogem Health Company S.L. is an healthcare company located in Mollet del Vallés, Barcelona,Spain. The company is a Spin-off of Inkemia IUCT Group, that focuses its attention on R&D and commercialitazion of new products against Rare Diseases.Everything started back in 2007 when Inkemia IUCT Group first started its research in Myotonic Dystrophy with a project called "New therapeutic Approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies", a Cetegen Project, funded by the Genome Spain Foundation, during which no exploitable results were obtained.The next project happened in 2009, thanks to the participation in a project called "La Marató de TV3". That edition that was particularly focused on fundraising for projects for the discovering of new treatments against rare diseases.During that edition more than 287 projects were presented but according to the proposal of the Scientific Advisory Committee of the Fundació La Marató de TV3, just 20 Research projects of excellence have been selected and funded with a total amount of 6.350.999 €.Among which, our project, named "Development of new treatments for Myotonic Dystrophy: discovery of drugs in vivo", was conducted thanks to the collaboration among three important Institutions.Inkemia IUCT group, under the supervision of Dr. Josep Castells, The University of Valencia (Faculty of Biological Sciences) represented by the Coordinatoor of the whole project Dr. Rubén Artero and the IQS (Institut Quimic de Sarriá) represented by the Dr. José I. Borrell and Dr. Jordi Teixidó.Because of those promising results it was decided to keep researching and, at the beginning of 2015, one of our projects with the acronym Myo-DM1 got the approval for a competitive program, PID of CDTI. This project's title is "Development of food supplements to improve the quality of life of patients suffering from Myotonic Distrophy type 1 (DM1)" and has a duration of approximately 2 years (2015-2017).